Boston Scientific reports steady Q1 2026 performance yet tempers FY26 outlook

Boston Scientific reported 11.2% year-over-year growth in Q1 2026 but reduced its full-year 2026 revenue guidance, trimming the top-end growth outlook by 2 percentage points. The adjustment signals caution amid what the company characterized as steady near-term performance across its device portfolio.